CompletedPhase 2

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

France, Ireland, United KingdomStarted 1998-11

Plain-language summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.

Who can participate

Age range6 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed metastatic rhabdomyosarcoma or other malignant mesenchymal tumors * Standard risk defined as: * Less than 10 years of age * No bone or bone marrow involvement * High risk defined as: * At least 10 years of age OR * Bone or bone marrow involvement * Diagnosed less than 8 weeks ago * Previously untreated disease except for initial surgery within the past 8 weeks PATIENT CHARACTERISTICS: Age: * 6 months to under 18 years Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior biologic therapy Chemotherapy: * No prior chemotherapy Endocrine therapy: * No prior endocrine therapy Radiotherapy: * Concurrent radiotherapy allowed Surgery: * See Disease Characteristics

Trial details

NCT IDNCT00025441

SponsorSociete Internationale d'Oncologie Pediatrique

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Ovarian Cancer trials